Eli Lilly | LLY - Assets


Eli Lilly reported $142.28B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Abbott USD 110.43B 23.72B Mar/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Baxter International USD 19.79B 55M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Drreddys Laboratories INR 579.35B 573.08B Mar/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
J&J USD 197.42B 3.64B Sep/2026
Medtronic USD 93.31B 278M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Phibro Animal Health USD 1.5B 56.12M Jun/2026
Prestige Brands USD 4.57B 1.07B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Sanofi EUR 128.02B 1.22B Mar/2026
United Therapeutics USD 7.22B 505.9M Jun/2026
Zoetis USD 15.08B 77M Jun/2026